Language-dependent variation in observed mechanistic performance of web-enabled large language models across myeloid–mucosal immune contexts: a blinded expert evaluation - Report - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Language-Dependent Differences in Mechanistic Performance of Web-Enabled Large Language Models in Myeloid-Mucosal Immune Contexts: An Expert Blinded Assessment

  • By

  • Jinxi Hu

  • Tong Mei

  • Lei Lin

  • Chengyan Xia

  • Tian Ma

  • Penghui Xiang

  • Wenzhuo Wang

  • Siqing Kong

  • Buorui Zhang

  • Sen Cao

  • Yutong Ge

  • Xiaochen Li

  • Lujie Zhang

  • Liangjing Xia

  • Hongliang Duan

  • Chengla Yi

  • September 15, 2026

Share

Clinical Report: Language-Dependent Differences in Mechanistic Performance of LLMs

Overview

This study evaluates the performance of web-enabled large language models (LLMs) across different languages in the context of myeloid-mucosal immunity. Significant language-dependent differences were observed in the mechanistic fidelity of model responses, highlighting the need for multilingual evaluation in biomedical contexts.

Background

The assessment of large language models in clinical settings is critical as they are increasingly utilized for decision support in healthcare. Understanding how these models perform across different languages is essential, especially given the complexities of mucosal immunity and the implications for patient care in diverse linguistic populations. This study addresses the gap in knowledge regarding the performance of LLMs in non-English contexts.

Data Highlights

No numerical data was provided in the source material.

Key Findings

  • Reviewer-standardized scores indicated a strong interaction between model and language for observed relative performance (F(12,191)=44.21, P<.001).
  • No significant model-by-complexity interaction was found (P =.328).
  • The highest mean Mechanistic Fidelity Scores (MFS) were for Kimi K3 (20.65) and ChatGPT 5.6 Sol (20.43).
  • Moderate-to-good inter-rater agreement was observed (Krippendorff α=0.709; Lin CCC = 0.709).
  • The omnibus model comparison was significant (F(4,23)=95.80, P<.001).
  • Multilingual biomedical evaluation should assess long-form mechanistic explanations in the intended language context.

Clinical Implications

The findings suggest that language can influence the performance of LLMs in clinical assessments, necessitating careful consideration when deploying these models in multilingual settings. Clinicians should be aware of potential discrepancies in model responses based on language and context.

Conclusion

The study underscores the importance of evaluating large language models in the specific languages and contexts they will be used, rather than relying solely on English performance metrics.

Related Resources & Content

  1. Author(s)/Org, Source, Year -- Title
  2. Author(s)/Org, Source, Year -- Title
  3. Author(s)/Org, Source, Year -- Title
  4. Author(s)/Org, Source, Year -- Title
  5. GINA Strategy Report 2026 Front Cover
  6. 2026 GOLD Report and Pocket Guide - Global Initiative for Chronic Obstructive Lung Disease - GOLD
  7. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment | Journal of Crohn's and Colitis | Oxford Academic
  8. ACG Clinical Guideline Update: Ulcerative Colitis... : American Journal of Gastroenterology
  9. ACG Clinical Guideline: Diagnosis and Management of Eosinophilic Esophagitis - PubMed
  10. Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation | New England Journal of Medicine
  11. Tezepelumab can Restore Normal Lung Function in Patients with Severe, Uncontrolled Asthma: Pooled Results from the PATHWAY and NAVIGATOR Studies - PMC
  12. Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn’s Disease | New England Journal of Medicine
  13. GINA Strategy Report 2026 Front Cover
  14. 2026 GOLD Report and Pocket Guide - Global Initiative for Chronic Obstructive Lung Disease - GOLD
  15. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment | Journal of Crohn's and Colitis | Oxford Academic
  16. ACG Clinical Guideline Update: Ulcerative Colitis... : American Journal of Gastroenterology
  17. ACG Clinical Guideline: Diagnosis and Management of Eosinophilic Esophagitis - PubMed
  18. Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation | New England Journal of Medicine
  19. Tezepelumab can Restore Normal Lung Function in Patients with Severe, Uncontrolled Asthma: Pooled Results from the PATHWAY and NAVIGATOR Studies - PMC
  20. Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn’s Disease | New England Journal of Medicine

Original Source(s)

Related Content